Magnova 250mg/31.25mg Injection
Marketer
Lupin Ltd
Salt Composition
Cefepime (250mg) + Tazobactum (31.25mg)
Overview Magnova 250mg/31.25mg Injection
Combiflox 250 mg/31.25 mg Injection, a dual-antibiotic formulation, combats diverse bacterial infections by inhibiting microbial proliferation. Administration requires strict medical oversight; missed doses should be avoided, and the full treatment course must be completed regardless of symptom improvement. Typical side effects include nausea, vomiting, diarrhea, and skin rashes. Injection site reactions (redness, swelling, pain) are also possible but usually transient. Severe or worsening side effects necessitate immediate consultation with a physician. Allergic reactions (skin rashes, itching, swelling, respiratory distress) demand urgent medical attention. Prior to use, disclose all current medications and health conditions to your doctor. This is especially crucial for pregnant or nursing individuals. Alcohol consumption should be avoided due to potential increased drowsiness. While generally not impairing driving ability, refrain from driving if drowsiness or dizziness occurs.
Primary Ingredients of Magnova 250mg/31.25mg Injection
The provided text is "undefined," so there is nothing to rephrase.
Uses of Magnova 250mg/31.25mg Injection
Infections caused by bacteria
Major Benefits of Magnova 250mg/31.25mg Injection:
This medication will be administered by your physician or their designated nurse. Self-medication is strictly prohibited.
Common Side effects of Magnova 250mg/31.25mg Injection:
- Diarrhea
- Increased white blood cell count (eosinophils)
- Injection site phlebitis
- Skin rash
- Increased liver enzymes
- Positive Coombs test
How to use Magnova 250mg/31.25mg Injection:
Administering this medication will be done by your doctor or nurse; please do not attempt self-medication.
How Magnova 250mg/31.25mg Injection works:
Magnova Injection, containing 250 mg cefepime and 31.25 mg tazobactam, combines a cephalosporin antibiotic with a beta-lactamase inhibitor. Cefepime's antibacterial action disrupts bacterial cell wall synthesis, hindering bacterial survival. Tazobactam counters bacterial enzymes that would otherwise deactivate cefepime, thus broadening Magnova's effectiveness and overcoming bacterial resistance mechanisms.
SAFETY ADVICE
AlcoholCAUTION
Using Magnova 250 mg/31.25 mg Injection with alcohol requires careful consideration. Seek medical advice before combining them.
PregnancySAFE IF PRESCRIBED
Administration of Magnova 250 mg/31.25 mg Injection is typically deemed safe for pregnant individuals. Preclinical trials using animals revealed minimal or no negative consequences for fetal development; however, research involving human subjects is currently insufficient.
Breast feedingSAFE IF PRESCRIBED
Magnova 250 mg/31.25 mg Injection poses minimal breastfeeding risk. Research in humans indicates negligible transfer to breast milk, presenting no appreciable danger to the infant.
DrivingUNSAFE
Following administration of Magnova 250 mg/31.25 mg Injection, temporary blurred vision may occur. Refrain from driving until visual acuity returns to normal.
KidneyCAUTION
Administering Magnova 250 mg/31.25 mg Injection to individuals with impaired renal function requires careful monitoring. Dosage modification for Magnova 250 mg/31.25 mg Injection might be necessary. Physician consultation is advised.
LiverSAFE IF PRESCRIBED
Magnova 250 mg/31.25 mg Injection appears safe for individuals with hepatic impairment. Available evidence indicates dose modification may be unnecessary; however, physician consultation is advised.
What if you forget to take Magnova 250mg/31.25mg Injection :
Should you forget a dose of Magnova 250 mg/31.25 mg Injection, seek medical advice.
Facts to Know About Magnova 250mg/31.25mg Injection
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Antimicrobial Agents |
3,018 People bought this recently